Table 1.
The demographic characteristics (mean ± standard deviation) and CYP2C19 genotyping of participants in this study.
| Age (y) | Body weight (kg) | Height (cm) | BMI | Gender Male [n(%)] | Gender Female [n(%)] | CYP2C19 EMs [n(%)] | CYP2C19 IMs [n(%)] | CYP2C19 PMs [n(%)] | |
|---|---|---|---|---|---|---|---|---|---|
| Vicagrel (5 mg; n = 9) | 30.1 (6.9) | 64.3 (10.6) | 167.1 (11.3) | 23.1 (3.3) | 7 (77.8) | 2 (22.2) | 6 (66.7) | 2 (22.2) | 1 (11.1) |
| Vicagrel (10 mg; n = 9) | 31.9 (5.0) | 63.7 (13.0) | 161.4 (11.2) | 24.3 (2.5) | 5 (55.6) | 4 (44.4) | 3 (33.3) | 5 (55.6) | 1 (11.1) |
| Vicagrel (15 mg; n = 9) | 28.1 (7.0) | 65.5 (10.9) | 166.6 (9.8) | 23.5 (2.6) | 5 (55.6) | 4 (44.4) | 2 (22.2) | 6 (66.7) | 1 (11.1) |
| Clopidogrel (n = 9) | 30.3 (7.5) | 63.8 (8.5) | 165.4 (7.2) | 23.4 (3.2) | 6 (66.7) | 3 (33.3) | 5 (55.6) | 4 (44.4) | 0 (0) |
| Placebo (n = 9) | 27.6 (7.5) | 61.3 (7.7) | 168.2 (8.2) | 21.6 (1.9) | 6 (66.7) | 3 (33.3) | 4 (44.4) | 5 (55.6) | 0 (0) |
| Vicagrel (loading dose of 30 mg and maintenance dose of 7.5 mg + aspirin at 100 mg) (n = 15) | 27.3 (4.4) | 63.1 (8.7) | 164.5 (9.5) | 23.3 (2.8) | 10 (66.7) | 5 (33.3) | 6 (40.0) | 6 (40.0) | 3 (20.0) |
| P (difference between 6 groups) | 0.5339 | 0.9312 | 0.6488 | 0.3450 | 0.8964 | 0.5967 | |||
| Total (n = 60) | 29.0 (6.3) | 63.6 (6.3) | 165.4 (9.5) | 23.2 (2.7) | 39 (65.0) | 21 (35.0) | 26 (43.3) | 28 (46.7) | 6 (10.0) |
BMI, body mass index; EMs, extensive metabolizers; IMs, intermediate metabolizers; PMs, poor metabolizers; n, sample size.
Statistically significance, P < 0.05.